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Abstract
Objectives
Rett syndrome is characterized by normal development for the first 
6-18 months of life followed by the loss of fine and gross motor 
skills and the ability to engage in social interaction. In most patients, 
mutations are found in methyl CpG-binding protein 2 (MECP2) gene. 
We investigated the relation between Rett clinical diagnosis and 
mutations in MECP2. 
Materials & Methods
Children suspected of Rett syndrome were invited to participate in this 
study. Twenty-three patients from the Mofid Hospital, Tehran, Iran 
suffered from classic Rett syndrome diagnostic criteria were enrolled 
in 2012. The severity of symptoms was assessed for all of them. 
The peripheral blood samples were collected in EDTA tubes and the 
genomic DNA was extracted using standard salting out method. The 
mutation of MEPC2 gene was studied using DNA sequencing method. 
Results 
Overall, 11(47.8%) patients had MECP2 gene mutation, while 12 
cases (52.2%) had no mutations. Changes in genetics were associated 
with phenotypical manifestations. The most prevalent mutation was 
p.v288 mainly associated with partially or uncontrolled seizures. 
Conclusion 
For the first time, we studies the Rett syndrome in terms of clinical 
manifestations and genetic changes in Iran.
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Introduction
Rett syndrome is a X-linked progressive brain 
developmental disorder and one of the most 
common causes of mental retardation in females 
first described in the 1960s by Andreas Rett (1). 
Girls affected with classic form of Rett syndrome 
(RTT) seem to have normal development for 6 to 
18 months. This course then followed by the loss 
of acquired fine and gross motor skills and the 
ability to engage in social interaction. Abnormal 
stereotypic hand movements may also occur. Rett 
syndrome primarily affects females and has an 
incidence of 1:10000 at birth until the age of 12 
years (2).
Rett syndrome has two main types: classic and 
atypical. These two types may be characterized 
by their symptoms or specific gene mutations, and 
most patients with Rett syndrome have a classic 
form (3).
Mutations in the X-linked gene methyl CpG-
binding protein 2 (MECP2) have been found in 
the majority of patients. MeCP2 is a protein that 
is critical for normal brain function. This protein 
is involved in maintaining synapses between nerve 
cells (4).
The mutations in the gene encoding MECP2 are 
associated with rare familial cases of RTT as well 
as in the usual sporadic cases of typical RTT (4). 
Using modern mutation detection tests, n 70%-
80% of patients with typical RTT mutations are 
found in MECP2 (5). In addition to RTT, mutations 
in MECP2 have also been identified in cases with 
no clinical features of RTT. 
Mutations are in the X-linked gene MECP2, which 
encodes MeCP2 protein. MeCP2 is a member of 
family of methyl-CpG-binding domain proteins 
(MBD), but with their unique differences that help 
put it apart from the group. More than 600 MECP2 
mutations have been identified, including missense, 
nonsense, frameshift and large deletion mutations 
that are pathogenic effect (RettBase; http://mecp2.
chw.edu.au/). Most of these changes in MECP2 
gene cause RTT in heterozygous females, but there 
is allelic heterogeneity in this disorder and a range 
of MECP2 mutations associated with variable 
phenotypic outcomes, including milder forms of 
learning disability and, rarely, autism, are also 
known (4, 6).
MECP2 has two functional domains, a methyl-
cytosine-binding domain (MBD) with composition 
of 85 amino acids and a transcriptional repression 
domain (TRD) which has 103 amino acids. The 
MBD domain binds to the methylation sites of CpG 
in the DNA strands and then TRD region makes 
reaction with SIN3A to utilize histone deacetylases 
(HDAC). There are also two high mobility group 
protein-like domains. The unusual, repetitive 
sequences are found at the carboxyl terminus (7, 8).
At one end of the spectrum, asymptomatic 
female carriers are found in familial RTT (11). 
Skewing of X chromosome inactivation (XCI) in 
these individuals allows them to have a normal 
presentation. At the other end of spectrum, boys 
with MECP2 mutations are confronted with severe 
early postnatal encephalopathy, early death, and 
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(9).
In addition to MECP2 mutations, cyclin-dependent 
kinase-like 5 (CDKL5) and Netrin G1, two other 
genes have recently been known in patients with 
clinical phenotype of Rett syndrome (10-14).
At present, a variety of clinical trials are done in 
RTT. As suggested in previous comprehensive 
studies conducted by Rett Search Consortium, 
clinical trials and other research studies to use a 
set of guidelines for classifying the disease (15). 
First, all individuals should be carefully reviewed 
and categorized clinically based on revised clinical 
criteria. The clinical diagnosis for all participants 
should be clearly stated in each publication. Second, 
comprehensive and complete genetic testing for 
mutations in MECP2 should be performed for all 
participants. This would include the sequencing of 
the coding region (15). 
We felt that Rett syndrome patients were not 
well studied in Iran. Therefore, we examined 
these patients based on the two main principals 
mentioned above to determine the spectrum of 
mutation in patients with Rett syndrome.
Materials & Methods 
Patients and samples
Twenty-three female children suspected of Rett 
syndrome referred to Neurology Outpatient Clinic, 
Mofid Hospital, Tehran, Iran in 2012 were invited 
to take part in this study. Referred individuals 
should have had a history of a period of relatively 
normal development after birth, followed by 
regression of developmental skills including the 
use of volitional hand, as well as reduced the speed 
of head circumference growth. The patients were 
enrolled in this study after observing the diagnostic 
criteria of classic Rett syndrome. The diagnosis 
of RTT was based exclusively on a set of clinical 
criteria derived from expert consensus (Table 1) 
(15). 
All examinations were performed by an expert 
pediatric neurologist. If any of them did not 
cooperate in the ongoing research, they were 
excluded from the study. For all included 
patients, severity of symptoms was assessed by 
a questionnaire. Locomotion, onset of signs and 
symptoms, seizure, head circumference growth, 
thrive, hand use, communication abilities, 
autonomic system disorders, EEG, scoliosis and 
self-abuse were graded from 0 to 3 to reflect 
severity of the signs and symptoms (Table 2). 
Informed consent was obtained from all the 
parents of patients for participation in this study.
Molecular Methods
MEPC2 gene mutation was studied by DNA 
sequencing method. We collected blood sample 
from suspected patients referred to genetic 
laboratory. The genomic DNA was extracted 
from peripheral blood in EDTA tubes by standard 
salting out method. DNA purity was assessed with 
a spectrophotometer and calculated by ratio of the 
DNA optical density (OD 260) and protein optical 
density (OD 280). DNA yield was calculated from 
DNA optical density (OD 260) for clean DNA 
samples. To avoid errors derived from Taq PCR 
polymerase, PCR was performed using PFU DNA 
polymerase (Fermentas, St. Leon-Rot, Germany). 
Finally, the reaction products were sequenced and 
examined by Chromas program.
Statistics
Having gathered patients’ data and molecular 
results, descriptive correlation between genotype 
and phenotype was finally investigated.
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Results
Of 27 patients who met the inclusion criteria, 23 
accepted to participate in the study. The mean age 
of 23 included patients in study was 5.2 yr with SD: 
±2.13. The minimum and maximum age was 2, and 
10 yr, respectively. The age of onset for signs and 
symptoms was ranged mostly less than 18 months 
(87%) and only 3 of 23 patients (13%) had shown 
their signs and symptoms in the range of 18-30 
months. According to the chart brought in methods 
section, the severity of signs and symptoms were 
defined from 0 (less sever) to 3 (most sever) pluses 
(Table 3).
In addition, frequencies for each of signs or 
symptoms were calculated. Of 23 included 
patients, 3 could walk without help, 12 needed help, 
4 needed devices to walk and 4 were disabled. Five 
patients were affected by uncontrolled Seizure, 
4 had partially controlled and 9 had controlled 
seizure, meanwhile five Rett syndrome patients had 
not any complaint of seizure. Head circumference, 
thrive, hand use, communication abilities, 
autonomic system disorders, EEG, Scoliosis and 
self-abuse descriptive results are brought in Table 
4. Regarding MECP2 gene mutation, 11 patients 
(47.8% of total included patients) had this mutation 
meanwhile 12 (52.2%) had no mutation.
Of all 13 patients who showed epilepsy, MECP2 
positive patients were more prone to have epilepsy. 
Eight epileptic patients had MECP2 mutation 
and the remaining 5 had not any evidence for 
MECP2 mutation. However, severity of epilepsy 
(uncontrolled seizures) was not related to MECP2. 
Similar results were seen in EEG abnormalities.
Hand use, psychomotor retardation and 
communication problems were seen in all patients 
either in MECP2 positives or negatives. Autonomic 
dysfunction was seen in 7 patients that only one of 
them had MECP2 mutation and other 6 ones had 
no evidence of mutation.
MEPC2 gene mutation was studied for each 
patient too. Ten patients showed evidence of 
nucleotide changes including missense, nonsense 
or frameshift. The rest of patients did not show 
any evidence of changes. The detail of the changes 
detected for each patient is brought in Table 5 and 
Figure 1.
Change in genetics is in association with 
phonotypical manifestations. The most prevalent 
mutation was p.v288 which is mostly in association 
with partially or uncontrolled seizures. Moreover, 
the patients affected with this mutation show 
severe EEG abnormalities. In addition, we found 
new frameshift mutation in this study.
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Table 1. Rett syndrome diagnostic criteria
Requirements
Consider diagnosis when postnatal deceleration of head growth obseved
Required for typical or classic RTT Required for atypical or variant RTT
1.A period of regression followed by recovery or 
stabilization
2.All main criteria and all exclusion criteria
3.supportive criteria are not required.although often 
present in typical RTT
1.A period of regression followed by recovery or 
stabilization
2.at least 2 of the 4 main criteria
3.5out of 11 supportive criteria
Criteria
Main criteria 1. Partial or complete loss of aquired purposeful hand skills
2. Partial or complete loss of aquired spoken language
3. Gait abnormalities:impaired or absence of ability
4. Stereotypic hand movements such as hand writing/
squeezing, clapping/tapping,mouthing and washing/rubbing 
automatism
Exclusion criteria for typical RTT 1.Brain injury secondary to trauma(peri- or 
postnataly),neurometabolic disease,or sever infection that 
causes neurological problems
2.Grossly abnormal psychomotor development in first 6 
months of life
Supportive criteria for atypical RTT 1. Breathing disturbance 
when awake
2. Bruxism when awake
3. Impaired sleep pattern
4. Abnormal muscle tone




8. Small cold hands and feet
9. Inappropriate laughing/
screaming spells
10. Diminshed response to 
pain
11. Intense eye 
communication”eye 
pointing”
Table 2. Signs and Symptoms severity assessment questionnaire
0 1 plus 2 pluses 3 pluses
Signs and Symptoms age of 
onset
No After 30 months 18-30 months
Less than 18 
months
Locomotion Without help With help With device Disable to walk
Seizure No Under control Partially controlled Uncontrolled
Head circumference growth Normal Less than 2SD Less than 3SD Less than 4SD
Thrive Normal Mild FTT Moderate FTT Sever FTT
Hand use Proper Grasping Moving toward Disable
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Communication abilities Proper -
Autonomic system disorders Normal Cold hands Cold hands and feet -
EEG Normal Mild abnormal Moderate abnormal Severe abnormal
Scoliosis No Mild Moderate Severe
Self abuse No Occasional Usual -




























1 ++ + + - + - + + - - + N*
2 - + + + ++ - ++ - ++ ++ - Y**
3 + + ++ + ++ + ++ + - - + N
4 - + - + + - + - + + - Y
5 ++ + + ++ + + + ++ +++ +++ - N
6 - + + - + - + + ++ ++ - N
7 - + + + + ++ + - + +++ - N
8 + + + + + + ++ - + ++ - Y
9 - + + + + - + - + - - N
10 - + + ++ + + ++ + - + - N
11 - + + +++ + - + - - - - N
12 - + + + + - + - - - - Y
13 ++ + - ++ ++ ++ +++ + + +++ +++ N
14 ++ + ++ +++ ++ - ++ ++ +++ +++ - Y
15 - + ++ + + + + - +++ ++ + N
16 - + +++ +++ ++ - ++ + - - - Y
17 ++ + + ++ + - ++ + +++ - - N
18 - + + + + - + - ++ ++ - Y
19 - + - + ++ - + + + + - N
20 - + + - + - ++ + + + + Y
21 ++ + + + + - ++ + ++ +++ + Y
22 - + ++ + ++ - + - +++ ++ - Y
23 - + + +++ + - + - - - - Y
* N stands for patients without genetic mutation  ** Y stands for patients with genetic mutation
Table 2: Continuted
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Table 5. Gene mutation for each patient 
Patient’s 
number
Nucleotide change Amino acid 
change
Type of Seq. 
change
References Figure




21 c.763C>T p.R255X Nonsense (25-33) 1B
2,14,22 c.862G>A p.V288M Missense (34) 1C
23 c.468C>G p.D156E Missense (35-41) 1D
20 c.880C>T p.R294X Nonsense (18, 25-31, 42) 1E
8 c.473C>T p.T158M Missense (18, 25-30, 42) 1F
4 c.397C>T p.R133C Missense (4, 17, 25, 26, 
29-31, 36, 37, 
42-55)
1G
12 c.502C>T p.R168X Nonsense (17, 18, 24-32, 
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Figure 1. Electrophoretogram of patients. Refer to the text and Table 5 for an explanation of the 
details of each mutation. 
 
Figure 1. Electrophoreto ram of patients. Refer to the text and Table 5 for an explanation of the details of each mutati n.
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Discussion
In this study, we reported the results of mutational 
analysis for MECP2 gene in Iranian affected RTT 
girls. To our knowledge, this was the first time 
that Rett patients were studied in both clinical 
manifestations and genetic changes in Iran. About 
47% of patients participated in our study showed 
MECP2 mutation including missense, nonsense or 
frame shift.
The rate of mutation detection in our study is equal 
to some previously reported rates such as the 50% 
detection rate. It confirms the major role of MECP2 
gene mutation in etiology of Iranian patients 
too (16). On the other hand, there is a difference 
comparing to findings of another study where 
nearly 70%-80% of females with Rett’s syndrome 
had these mutations within the MECP2 gene (5).
Of note, MECP2 positivity differs in various 
countries, as De novo mutations were found in 
60% of the patients in Spain which is closer to our 
findings (17). This difference is also referred to the 
limited number of patients studied in such studies 
and a series of patient who refused to participate 
like happened in our research. This reason could 
explain when comparing the results of a study in 
Japan in which 19 disease mutations (73%) were 
identified in 26 Japanese Rett patients (18).
The mutational diversity in our patients is consistent 
with the findings of other studies (16-18). In our 
study, about 10% of mutations were intragenic 
deletions or complex rearrangements that lead to 
frameshifts. In our study, of 10 MECP2 positive 
mutations, we detected one case with frameshift in 
the C-terminal region. 
Moreover, the majority of mutations was C>T 
transitions which were nearly 70% of all identified 
mutations. Similarly, the majority of mutations in 
our study was C>T transitions too which was about 
50% in another study (19).
The p.V288M amino acid change is identified as 
the most common mutational hotspot in our study. 
However, this mutation is not included in common 
formerly recognized hot spots. This is a new 
finding in patients with Rett syndrome in Iranian 
population.
In a previous study, 70% of the mutations within 
MECP2 were in eight hotspots which affect 
translation of the amino acids including R106, 
R133, T158, R168, R255, R270, R294, and R306 
(20).
According to patients’ signs and symptoms, 
despite in some items like epilepsy and EEG 
abnormalities, MECP2 positives showed slightly 
higher rates compared to those without mutations, 
and autonomic dysfunctions were more seen in 
MECP2 negatives, but none of them revealed 
significant correlation between signs and mutations. 
Moreover, severity of signs and symptoms is not in 
relation with gene mutation and loci of mutation 
in our research. The only exception refers to sever 
EEG abnormality seen in patients with p.V288M 
amino acid change. 
Location and frequency of MeCP2 ‘‘hotspot’’ 
mutations in RTT patients show that most of these 
mutations are point substitutes in nucleotides 
including R106W, arginine to tryptophan point 
mutation at residue 106; R133C, arginine to 
cysteine point mutation at residue 133; T158M, 
threonine to methionine point mutation at residue 
158; R168X, arginine to stop codon at residue 
168; R255X, arginine to stop codon at residue 
255; R294X, arginine to stop codon at residue 
294; R306C, arginine to cysteine point mutation at 
residue 306. The amino acids 207and 310 of TRD 
are involved in the repression of transcription of 
target genes, but the mechanism of TRD repression 
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is unknown (21).
The study of genotype-phenotype correlation 
requires precise investigations in larger group of 
patients to determine correlation with various 
types of mutations.
Genotype-phenotype correlation has been 
investigated, but it is complex by MECP2 gene 
X-chromosome inactivation. This inactivity 
allows a mother with a mutation of MECP2 to 
have a normal phenotype because of skewing of 
X-chromosome inactivation (22). In contrast to the 
problems with X-chromosome inactivation, many 
studies of genotype-phenotype correlations exist 
(17, 22, 23).  More studies must be carried out to 
investigate more case to find better conclusions.
In conclusion, our results together with data 
reported by others allow general conclusions about 
the MECP2 mutational spectrum and growth/
developmental manifestations or phenotypes.
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